Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70

Guggenheim analyst Brad Canino has initiated coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating. The firm has set a price target of $70 for the stock.